Quantcast
Last updated on April 17, 2014 at 9:10 EDT

Latest Tapentadol Stories

2013-10-16 04:21:51

BARCELONA, Spain, October 16, 2013 /PRNewswire/ -- - The results of the study, in patients with acute postoperative moderate to severe pain, show that E-58425 demonstrated superior efficacy and safety over both placebo and a standard of care - E-58425 is a novel, first-in-class, patented, co-crystal product entity - The positive phase II data confirm the Product Concept of E-58425: Clinically relevant and robust pain...

2013-10-15 08:30:36

First medical meeting data presentations from Phase 3 clinical trial conducted in orthopedic surgery patients REDWOOD CITY, Calif., Oct. 15, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced presentations of its previously reported Phase 3 data for Zalviso(TM) (sufentanil sublingual microtablet system) at...

2013-09-26 16:26:53

Company to Host Conference Call on Thursday, September 26th at 1:30 PM Pacific Time/4:30 PM Eastern Time to Discuss Results SAN FRANCISCO, Sept. 26, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced the preliminary topline results from a Phase 2 study of NKTR-181 for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis of the knee. The Phase 2 study utilized a double-blind, placebo-controlled, randomized withdrawal study design to assess...

2013-09-05 08:28:50

Randomized, Placebo-Controlled Study to Evaluate Safety and Efficacy of AYX1 in Prevention of Pain Following Total Knee Replacement SAN FRANCISCO, Sept. 5, 2013 /PRNewswire/ -- Adynxx, a clinical-stage pharmaceutical company developing a transformative, first-in-class platform of therapeutics to address pain at its molecular roots, announced today the completion of enrollment in a Phase 2 clinical study of its lead product candidate, AYX1, for reduction of acute post-surgical pain...

2013-07-30 08:32:46

ALBANY, New York, July 30, 2013 /PRNewswire/ -- New Market Research Report Added in MarketResearchReports.Biz Reports Database Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline...

2013-07-17 08:26:25

AYX1 Injection Designated as a Fast Track Development Program for Prevention of Chronic Pain SAN FRANCISCO, July 17, 2013 /PRNewswire/ -- Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AYX1 Injection for the prevention of chronic pain. "Fast Track designation for the AYX1 program is an...

2013-07-08 08:26:19

CAMBRIDGE, England, July 8, 2013 /PRNewswire/ -- Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with diabetic peripheral neuropathy (DPN). Results from the study are expected in the second half of 2014. The trial is a randomised double-blind,...

2013-06-18 08:30:40

The patent covers the process and preparation of Tapentadol for the treatment of moderate to severe-acute pain NESS ZIONA, Israel, June 18, 2013 /PRNewswire/ -- Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the company has been granted a United States patent for Tapentadol. Tapentadol is indicated in the US...

2013-06-12 23:26:24

Oxycodone is mostly used as pain medication, yet it can become habit forming. Recovery Associates´ therapists, counselors and programs help individuals heal from addictive ways. West Palm Beach, FL (PRWEB) June 12, 2013 Oxycodone is a medication that provides relief to individuals suffering from moderate to severe pain symptoms. It has been known to lead people down an addictive path — one that leaves them wanting more medication. Oxycodone is an opioid pain medication, and an...

2013-05-08 08:30:13

CANTON, Mass., May 8, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the presentation of a scientific poster titled "Oxycodone DETERx®, an Extended-release, Abuse-deterrent Formulation for the Management of Chronic Pain," at the American Pain Society's 32(nd) Annual Scientific Meeting, held in New Orleans, Louisiana from May 8(th) to May 10(th). This...